login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Mixed evidence on use of radiofrequency catheter ablation for AF


Monday, 13 Jul 2009 13:24
Carolyn Clancy
Carolyn Clancy


Little is known about the long-term benefits catheter ablation for atrial fibrillation and the best methods and circumstances for applying it, according to a new report funded by the US Department of Health & Human Services’s (HHS) Agency for Healthcare Research and Quality (AHRQ).


The report examines the use of radiofrequency catheter ablation to treat AF. The new comparative effectiveness report found that the procedure has been shown to provide benefits in maintaining normal heart rhythm over short periods of time (up to one year) but found little evidence indicating whether the procedure reduces the chance that patients will experience atrial fibrillation over the long term.


The report, which compared radiofrequency ablation to medication-based therapy, also found that the effect of the procedure on stroke, a major risk for patients with atrial fibrillation, is unknown.
"Radiofrequency holds promise for treating atrial fibrillation, but it is clear that more research is needed to demonstrate its potential long-term benefits," said AHRQ director Carolyn M Clancy. "This report crystallises the questions that researchers need to ask going forward."


The report calls for more research on the effect of catheter ablation on quality of life. In particular, more research is needed for groups of patients for whom the research is especially lacking, such as women, the elderly, and patients who have other conditions such as heart failure or high blood pressure.


Earlier this year, HHS’ FDA approved the first two ablation catheters indicated for use in treating atrial fibrillation, in the US. However, physicians often use other catheters that have not been approved by the FDA for atrial fibrillation. The FDA also found that there is no conclusive evidence that people whose symptoms are reduced with ablation are less likely to have a stroke. Therefore, the FDA explicitly endorsed existing clinical guidelines that recommend that patients at risk for stroke continue to take preventive blood-thinning medications after radiofrequency catheter ablation.


As a condition of catheter approvals, the FDA mandated that the catheters’ manufacturer must conduct two post approval studies (PAS) to collect long term safety data. The mandated studies apply only to FDA-approved catheters, and not to devices used off-label in clinical practice. The first PAS is a post approval registry, which will collect safety (adverse event) data and operator experience information through seven days post-treatment with the approved ablation catheters. The study will also collect data on long-term safety data, such as death, stroke, myocardial infarction, clinically manifested pulmonary vein stenosis, etc., at five years post-treatment. The second PAS is a subgroup analysis from an ongoing larger study that will look at the incidence of stroke, and compare the three-year incidence of stroke between patients treated with the approved ablation catheters versus patients treated with medication. This study will analyse total mortality, serious bleeding and cardiac arrest.


Also, last week, the FDA approved a new medication, dronedarone, for treatment of atrial fibrillation.


Information, including the new report, can be found at www.effectivehealthcare.ahrq.gov.




Add New Comment

Most popular


Long-term sustained weight loss associated with significant reduction in AF burden
Friday, 27 Mar 2015
The first study investigating the long-term effects of weight loss and the degree of weight fluctuation on atrial fibrillation (AF) burden has found that obese patients with this arrhythmia who lost ... Long-term sustained weight loss associated with significant reduction in AF burden

Medtronic initiates study evaluating potential of combination of pulmonary vein isolation and renal denervation for atrial fibrillation
Friday, 01 May 2015
Medtronic has announced the start of a clinical study using Medtronic technologies to determine whether paroxysmal and persistent atrial fibrillation can be treated with a combination of two ablation ... Medtronic initiates study evaluating potential of combination of pulmonary vein isolation and renal denervation for atrial fibrillation

Medtronic’s Micra Transcatheter Pacing System gets CE mark
Tuesday, 14 Apr 2015
The device is less than one-tenth the size of traditional pacemakers and is delivered with minimally invasive techniques through a catheter, and implanted directly into the heart. Medtronic’s Micra Transcatheter Pacing System gets CE mark

Features


Antibacterial envelopes help to reduce infection rates and healthcare costs in high-risk CIED patients
Tuesday, 07 Apr 2015
A strategy using an antibacterial envelope is showing promising results reducing infection rates and cutting on healthcare costs in high-risk cardiac implantable electronic devices patients. Antibacterial envelopes help to reduce infection rates and healthcare costs in high-risk CIED patients

SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea
Tuesday, 24 Mar 2015
Martin Cowie (Imperial College London, London, UK) is the principal investigator of the SERVE-HF study, which is assessing the use of adaptive servo-ventilation (PaceWave, ResMed) in chronic heart ... SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea

Profiles


Hung-Fat Tse
Tuesday, 03 Feb 2015
While Hung-Fat Tse’s initial research interests focused on device therapy for cardiac arrhythmias, ... Hung-Fat Tse

Massimo Santini
Friday, 10 Oct 2014
Massimo Santini performed the first fulguration of the atrioventricular node of resistant ... Massimo Santini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions